Related Experiment Video
Updated: Mar 21, 2026

Formation of Dispersible Taohong Siwu Tablets
Published on: February 3, 2023
Cyclodextrin-based telmisartan ophthalmic suspension: Formulation development for water-insoluble drugs
Chutimon Muankaew1, Phatsawee Jansook2, Hákon Hrafn Sigurđsson3
1Faculty of Pharmaceutical Sciences, University of Iceland, Hofsvallagata 53, IS-107 Reykjavik, Iceland; Faculty of Pharmacy, Siam University, 38 Petkasem Road, Phasicharoen, Bangkae, Bangkok 10160, Thailand.
Abstract:
In this study, cyclodextrin-based aqueous eye drop suspension of the water insoluble drug telmisartan was developed. Formation of a drug/γ-cyclodextrin complex was enabled by preventing formation of a poorly water-soluble zwitterion using a volatile base that was removed upon drying of the complex powder. Hydroxypropyl methylcellulose was shown to have the overall best effect, stabilizing the complexes without hampering the drug release from the formulation. Two strategies for preparing cyclodextrin-based aqueous eye drop suspensions of telmisartan were investigated, one where hydroxypropyl methylcellulose was added to the medium during preparation of the drug/γ-cyclodextrin complex powder (ternary complex) and the other where hydroxypropyl methylcellulose was added to the complex powder after preparation of the complex (binary complex). The complexation was characterized by DSC, FT-IR and (1)H NMR and the eye drop suspensions formed were examined regarding their stability and in vitro mucoadhesion property. The ternary complex exhibited inferior mucoadhesive property compared to the binary complex. However, the ternary complex was more stable as no notable change in particle size and particle size distribution was observed during storage at 4°C over 6 months (p<0.05) with the mean particle size determined between 2.0 and 2.5μm.
Related Concept Videos
Ophthalmic Drug Delivery Systems
Oral Drug Delivery Systems: Continuous-Release Systems
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Modified-Release Drug Delivery Systems: Rate-Programmed II
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

